|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Alnylam Pharmaceuticals
|
Analyst Conference Notes by William P. Meyers |
|||
2018 |
|||
Alnylam Q4 2018 |
|||
May 3, 2018 |
August 2, 2018 |
Nov. 7, 2018 |
Feb. 7, 2019 |
2017 |
|||
May 5, 2017 |
August 9, 2017 |
Nov. 7, 2017 |
Feb. 8, 2018 |
2016 |
|||
05/02/2016 |
08/04/2016 |
11/02/2016 |
02/08/2017 |
2015 |
|||
05/07/2014 |
08/06/2015 |
11/09/2015 |
02/11/2016 |
Alnylam Pharmaceuticals (ALNY) is a clinical-stage developer of RNAi based therapies.
I sold my remaining ALNY stock on October 9, 2017. I may buy again if the stock price or developments make it attractive, by my standards, again.
More Analyst Conference Pages:
AGEN |
ALNY |
ALXN |
AMAT |
AMD |
AMGN |
BIIB |
CELG |
EPZM |
GILD |
GLYC |
INO |
INTC |
ISRG |
MACK |
MCHP |
MRVL |
MYL. |
NVDA |
REGN |
SGEN |
XLNX |
XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2018 William P. Meyers